Cargando…
Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
BACKGROUND: Unfractionated heparin sodium and nafamostat mesylate have long been used as anticoagulants in continuous kidney replacement therapy (CKRT) where citrate is unavailable. This study aimed to determine whether heparin or nafamostat mesylate used during CKRT was associated with a longer fil...
Autores principales: | Kameda, Shinya, Fujii, Tomoko, Ikeda, Junpei, Kageyama, Akira, Takagi, Toshishige, Miyayama, Naoki, Asano, Kengo, Endo, Arata, Uezono, Shoichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840945/ https://www.ncbi.nlm.nih.gov/pubmed/36642717 http://dx.doi.org/10.1186/s12882-023-03060-1 |
Ejemplares similares
-
Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023) -
Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015) -
Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023) -
Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020) -
Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)